These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 16719831)
1. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. Ramachandran U; Kumar R; Mittal A Mini Rev Med Chem; 2006 May; 6(5):563-73. PubMed ID: 16719831 [TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Jay MA; Ren J Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654 [TBL] [Abstract][Full Text] [Related]
3. PPAR dual agonists: are they opening Pandora's Box? Balakumar P; Rose M; Ganti SS; Krishan P; Singh M Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674 [TBL] [Abstract][Full Text] [Related]
4. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors. Yumuk VD Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746 [TBL] [Abstract][Full Text] [Related]
5. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Mansour M Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239 [TBL] [Abstract][Full Text] [Related]
6. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome. Pershadsingh HA Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049 [TBL] [Abstract][Full Text] [Related]
7. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Tenenbaum A; Motro M; Fisman EZ Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052 [TBL] [Abstract][Full Text] [Related]
8. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Gross B; Staels B Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742 [TBL] [Abstract][Full Text] [Related]
9. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists. Gervois P; Fruchart JC; Staels B Int J Clin Pract Suppl; 2004 Oct; (143):22-9. PubMed ID: 16035393 [TBL] [Abstract][Full Text] [Related]
10. Safety issues and prospects for future generations of PPAR modulators. Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730 [TBL] [Abstract][Full Text] [Related]
15. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). Tjokroprawiro A Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268 [TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. Guan Y J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933 [TBL] [Abstract][Full Text] [Related]
18. A new insight into the treatment of diabetes by means of pan PPAR agonists. Chandra A; Kaur P; Sahu SK; Mittal A Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085 [TBL] [Abstract][Full Text] [Related]
19. Advances and Challenges in Drug Design of PPARĪ“ Ligands. Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978 [TBL] [Abstract][Full Text] [Related]
20. [PPAR family and its relationship to metabolic syndrome]. Zhang XY; Chen LH; Guan YF Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]